Notably, an explanation for the diverging and more severe phenotype of many other transgenic AD mouse models may be sought in the fact that those models are far removed from the human disease state, with non-endogenous promotors, overexpression of APP byproducts, PS1 mutation and/or abnormal APP and Aβ expression levels. The gene discussed is APP; the disease is Alzheimer disease.